Waheed Nadia sold $123K of OCUL
Waheed Nadia (Chief Medical Officer) sold 14,828 shares of OCULAR THERAPEUTIX, INC (OCUL) at $8.27 ($0.12M total) on 2026-06-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure confirms an open-market sale executed June 3 at $8.27/share, with remaining holdings of 300,079 shares, under a pre-arranged 10b5-1 plan.
Market read
Provides a fresh insider-selling datapoint for OCUL, but lacks new fundamental catalysts.
What to watch
Insider sale size relative to total holdings and whether future scheduled sales cluster could matter more than this single print.
Background
This is an SEC Form 4 insider transaction disclosure (officer/direct sale) for OCULAR THERAPEUTIX.
Ticker impact
OCULAR THERAPEUTIX disclosed CMO Waheed Nadia sold 14,828 shares in an open-market transaction under a 10b5-1 plan.
Likely limited immediate price impact; any reaction should be modest unless accompanied by other company-specific catalysts.
The filing provides a concrete insider sale datapoint (size, price, timing) but no new operational/clinical/regulatory information.
Market effects
Minimal—single-company insider transaction without accompanying sector/regulatory change.
None indicated.
None indicated.
Counterpoint
Because the sale is pre-arranged, traders may overreact less; any price dip could be viewed as an opportunity if no other negatives emerge.
Key entities
- issuerOCULAR THERAPEUTIX, INC
Company whose officer transaction was reported on SEC Form 4.
- insiderWaheed Nadia
Chief Medical Officer who sold 14,828 shares under a 10b5-1 plan.
